INCY · Incyte Corporation

Incyte Corporation reported a strong first quarter of 2026, with total revenue climbing 21% to $1.27 billion, surpassing the $1 billion net sales milestone for the first time. This performance was anchored by robust demand for Jakafi, which grew 7% to $758 million, and significant contributions from newer products. Notably, Niktimvo sales surged 305% to $55 million, and Zynyz sales increased by 1,276% to $41 million, reflecting successful commercial execution and label expansions. The Hematology and Oncology portfolio grew 116%, partially offsetting slower growth in Monjuvi/Minjuvi.

Profitability metrics showed substantial improvement, with GAAP net income rising to $303 million compared to $158 million in the prior year period. Non-GAAP diluted EPS of $1.81 reflected strong operational leverage, despite a 19% increase in non-GAAP R&D expenses to $477 million. Management highlighted the progression of the late-stage pipeline, now comprising 10 Phase 3 studies, including the initiation of a pivotal trial for INCB161734 in pancreatic cancer. The company also announced positive Phase 3 results for povorcitinib in nonsegmental vitiligo, supporting planned regulatory submissions in the first half of 2027. Additionally, Suketu Upadhyay was appointed CFO, effective May 4, 2026, bringing extensive financial leadership experience from Zimmer Biomet and Bristol Myers Squibb. The balance sheet remains strong with $4.0 billion in cash and marketable securities.